{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T06:55:35Z","timestamp":1771570535032,"version":"3.50.1"},"reference-count":117,"publisher":"Edizioni Minerva Medica","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Panminerva Med"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.23736\/s0031-0808.25.05314-5","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T06:37:03Z","timestamp":1748932623000},"source":"Crossref","is-referenced-by-count":1,"title":["An overview of recent developments in clinical trials of anti-diabetic drugs"],"prefix":"10.23736","volume":"67","author":[{"given":"Yeduvaka","family":"MADHURI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qazi","family":"SAIFULLAH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"PANDEY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subrat K.","family":"BHATTAMISRA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17149","reference":[{"key":"10.23736\/S0031-0808.25.05314-5_ref001","first-page":"45","article-title":"Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links","volume":"11","author":"Oguntibeju OO","year":"2019","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"10.23736\/S0031-0808.25.05314-5_ref002","doi-asserted-by":"publisher","DOI":"10.2174\/1573399819666230413094200"},{"key":"10.23736\/S0031-0808.25.05314-5_ref003","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.151"},{"key":"10.23736\/S0031-0808.25.05314-5_ref004","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3676"},{"key":"10.23736\/S0031-0808.25.05314-5_ref005","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S002"},{"key":"10.23736\/S0031-0808.25.05314-5_ref006","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115734"},{"key":"10.23736\/S0031-0808.25.05314-5_ref007","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12791"},{"key":"10.23736\/S0031-0808.25.05314-5_ref008","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.02.023"},{"key":"10.23736\/S0031-0808.25.05314-5_ref009","doi-asserted-by":"publisher","DOI":"10.2991\/jegh.k.191028.001"},{"key":"10.23736\/S0031-0808.25.05314-5_ref010","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1797-8"},{"key":"10.23736\/S0031-0808.25.05314-5_ref011","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176275"},{"key":"10.23736\/S0031-0808.25.05314-5_ref012","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405"},{"key":"10.23736\/S0031-0808.25.05314-5_ref013","doi-asserted-by":"publisher","DOI":"10.2337\/db10-1032"},{"key":"10.23736\/S0031-0808.25.05314-5_ref014","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62154-6"},{"key":"10.23736\/S0031-0808.25.05314-5_ref015","doi-asserted-by":"publisher","DOI":"10.2337\/diab.37.6.667"},{"key":"10.23736\/S0031-0808.25.05314-5_ref016","doi-asserted-by":"publisher","DOI":"10.2337\/db09-9028"},{"key":"10.23736\/S0031-0808.25.05314-5_ref017","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00617.2005"},{"key":"10.23736\/S0031-0808.25.05314-5_ref018","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115997"},{"key":"10.23736\/S0031-0808.25.05314-5_ref019","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011035"},{"key":"10.23736\/S0031-0808.25.05314-5_ref020","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.02.017"},{"key":"10.23736\/S0031-0808.25.05314-5_ref021","doi-asserted-by":"publisher","DOI":"10.1038\/nature05485"},{"key":"10.23736\/S0031-0808.25.05314-5_ref022","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.06.019"},{"key":"10.23736\/S0031-0808.25.05314-5_ref023","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1326"},{"key":"10.23736\/S0031-0808.25.05314-5_ref024","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.1.102"},{"key":"10.23736\/S0031-0808.25.05314-5_ref025","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.07.029"},{"key":"10.23736\/S0031-0808.25.05314-5_ref026","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0037"},{"key":"10.23736\/S0031-0808.25.05314-5_ref027","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0023"},{"key":"10.23736\/S0031-0808.25.05314-5_ref028","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-3965-9"},{"key":"10.23736\/S0031-0808.25.05314-5_ref029","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e32833a558d"},{"key":"10.23736\/S0031-0808.25.05314-5_ref030","doi-asserted-by":"publisher","DOI":"10.1177\/0748730417713572"},{"key":"10.23736\/S0031-0808.25.05314-5_ref031","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003200"},{"key":"10.23736\/S0031-0808.25.05314-5_ref032","doi-asserted-by":"publisher","DOI":"10.1016\/j.jada.2010.03.017"},{"key":"10.23736\/S0031-0808.25.05314-5_ref033","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v4.i4.114"},{"key":"10.23736\/S0031-0808.25.05314-5_ref034","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2018.10.003"},{"key":"10.23736\/S0031-0808.25.05314-5_ref035","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.bmb.a011611"},{"key":"10.23736\/S0031-0808.25.05314-5_ref036","first-page":"s176","article-title":"Obesity: definition, comorbidities, causes, and burden","volume":"22","author":"Apovian CM","year":"2016","journal-title":"Am J Manag Care"},{"key":"10.23736\/S0031-0808.25.05314-5_ref037","doi-asserted-by":"publisher","DOI":"10.1007\/s11745-003-1038-4"},{"key":"10.23736\/S0031-0808.25.05314-5_ref038","doi-asserted-by":"publisher","DOI":"10.1016\/j.eehl.2024.07.001"},{"key":"10.23736\/S0031-0808.25.05314-5_ref039","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-18766-6"},{"key":"10.23736\/S0031-0808.25.05314-5_ref040","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad422"},{"key":"10.23736\/S0031-0808.25.05314-5_ref041","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13759-9"},{"key":"10.23736\/S0031-0808.25.05314-5_ref042","doi-asserted-by":"publisher","DOI":"10.1093\/inthealth\/ihac060"},{"key":"10.23736\/S0031-0808.25.05314-5_ref043","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1330650"},{"key":"10.23736\/S0031-0808.25.05314-5_ref044","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-04895-4"},{"key":"10.23736\/S0031-0808.25.05314-5_ref045","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13133927"},{"key":"10.23736\/S0031-0808.25.05314-5_ref046","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25081987"},{"key":"10.23736\/S0031-0808.25.05314-5_ref047","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2018.10.008"},{"key":"10.23736\/S0031-0808.25.05314-5_ref048","first-page":"304","article-title":"IDF-MENA Region Guidelines for the Management of Type 2 Diabetes","volume":"6","author":"Basit A","year":"2015","journal-title":"Diabetes"},{"key":"10.23736\/S0031-0808.25.05314-5_ref049","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-S120"},{"key":"10.23736\/S0031-0808.25.05314-5_ref050","doi-asserted-by":"publisher","DOI":"10.1249\/MSS.0b013e3181b3b16d"},{"key":"10.23736\/S0031-0808.25.05314-5_ref051","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2013.02.060"},{"key":"10.23736\/S0031-0808.25.05314-5_ref052","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.36.4.1705"},{"key":"10.23736\/S0031-0808.25.05314-5_ref053","doi-asserted-by":"publisher","DOI":"10.4158\/EP12160.PS"},{"key":"10.23736\/S0031-0808.25.05314-5_ref054","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.21.2005"},{"key":"10.23736\/S0031-0808.25.05314-5_ref055","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12995"},{"key":"10.23736\/S0031-0808.25.05314-5_ref056","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_556_17"},{"key":"10.23736\/S0031-0808.25.05314-5_ref057","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2015.53304"},{"key":"10.23736\/S0031-0808.25.05314-5_ref058","doi-asserted-by":"publisher","DOI":"10.1080\/21548331.1999.11443925"},{"key":"10.23736\/S0031-0808.25.05314-5_ref059","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133316"},{"key":"10.23736\/S0031-0808.25.05314-5_ref060","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4336-x"},{"key":"10.23736\/S0031-0808.25.05314-5_ref061","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2004.059"},{"key":"10.23736\/S0031-0808.25.05314-5_ref062","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-019-1270-y"},{"key":"10.23736\/S0031-0808.25.05314-5_ref063","first-page":"1171","article-title":"Pathophysiology and treatment of type 2 diabetes mellitus: A Review","volume":"11","author":"Banwari M","year":"2023","journal-title":"J Coast Life Med"},{"key":"10.23736\/S0031-0808.25.05314-5_ref064","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01526.x"},{"key":"10.23736\/S0031-0808.25.05314-5_ref065","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2012.31621"},{"key":"10.23736\/S0031-0808.25.05314-5_ref066","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.2007.S434"},{"key":"10.23736\/S0031-0808.25.05314-5_ref067","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2018.07.009"},{"key":"10.23736\/S0031-0808.25.05314-5_ref068","doi-asserted-by":"publisher","DOI":"10.1042\/CS20040302"},{"key":"10.23736\/S0031-0808.25.05314-5_ref069","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00389"},{"key":"10.23736\/S0031-0808.25.05314-5_ref070","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00260"},{"key":"10.23736\/S0031-0808.25.05314-5_ref071","doi-asserted-by":"publisher","DOI":"10.2174\/1874104501105010078"},{"key":"10.23736\/S0031-0808.25.05314-5_ref072","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S1978"},{"key":"10.23736\/S0031-0808.25.05314-5_ref073","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.suppl_3.S233"},{"key":"10.23736\/S0031-0808.25.05314-5_ref074","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0337-y"},{"key":"10.23736\/S0031-0808.25.05314-5_ref075","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16162965"},{"key":"10.23736\/S0031-0808.25.05314-5_ref076","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000311"},{"key":"10.23736\/S0031-0808.25.05314-5_ref077","first-page":"59","article-title":"Modern-Day Therapeutics and Ongoing Clinical Trials against Type 2 Diabetes Mellitus: A Narrative Review","volume":"21","author":"Tiwari RK","year":"2025","journal-title":"Curr Diabetes Rev"},{"key":"10.23736\/S0031-0808.25.05314-5_ref078","unstructured":"A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus. Identifier NCT05048719; 2022 [Internet]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05048719 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref079","unstructured":"A Study of LY3437943 in Participants With Type 2 Diabetes. Identifier NCT04867785; 2022 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04867785 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref080","unstructured":"A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (SURMOUNT-2). Identifier NCT04657003; 2023 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04657003 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref081","unstructured":"A Study to Evaluate the Effect of ORMD-0801 in Patients With Type 2 Diabetes Mellitus. Identifier NCT04564846; 2022 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04564846 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref082","unstructured":"Phase A. 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus. Identifier NCT04450394; 2021 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04450394 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref083","unstructured":"A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India. Identifier NCT04153981; 2021 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04153981 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref084","unstructured":"A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. Identifier NCT04153929; 2021 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04153929 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref085","unstructured":"A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus. Identifier NCT04050553; 2022 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04050553 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref086","unstructured":"A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus. Identifier NCT03985293; 2021 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03985293 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref087","unstructured":"A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM). Identifier NCT03951753; 2021 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03951753 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref088","unstructured":"A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes. Identifier NCT03861039; 2021 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03861039 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref089","unstructured":"A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus. Identifier NCT03745937; 2019 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03745937 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref090","unstructured":"IDegLira HIGH Trial. Identifier NCT03737240; 2022 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03737240 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref091","unstructured":"A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus. Identifier NCT03736785; 2020 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03736785 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref092","unstructured":"Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes. Identifier NCT03645421; 2019 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03645421 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref093","unstructured":"A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes (AWARD-11). Identifier NCT03495102; 2020 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03495102 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref094","unstructured":"Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria. Identifier NCT03449199; 2019 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03449199 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref095","unstructured":"Effect of Propolis or Metformin Administration on Glycemic Control in Patients With Type 2 Diabetes Mellitus. Identifier NCT03416127; 2019 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03416127 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref096","unstructured":"Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects. Identifier NCT03406377; 2019 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03406377 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref097","unstructured":"Phase A. 1\/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM. (2023, March - 2025, December); Identifier NCT05761301; 2025 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05761301 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref098","unstructured":"Hangzhou Sciwind Biosciences Co. LC. A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM. Identifier NCT05680129; 2023 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05680129 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref099","unstructured":"Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM. Identifier NCT05677334; 2024 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05677334 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref100","unstructured":"HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes (CENTRICITY). Identifier NCT05623189; 2025 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05623189 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref101","unstructured":"Sciwind Biosciences US. Co. LUS. XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM). Identifier NCT05579314; 2025 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05579314 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref102","unstructured":"Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease. Identifier NCT05514548; 2024 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05514548 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref103","unstructured":"Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD). (TRUTH-DKD). Identifier NCT05469659; 2025 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05469659 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref104","unstructured":"Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD). Identifier NCT05459701; 2024 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05459701 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref105","unstructured":"Newsoara Biopharma Co. LC. Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects. Identifier NCT05369078; 2022 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05369078 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref106","unstructured":"A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM). Identifier NCT05327595; 2024 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05327595 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref107","unstructured":"A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both (SURPASS-PEDS). Identifier NCT05260021; 2025 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05260021 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref108","unstructured":"PegBio Co. LC. Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus. Identifier NCT05102149; 2022 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05102149 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref109","unstructured":"IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics. Identifier NCT04982705; 2022 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04982705 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref110","unstructured":"Phase A. 1 Study of DD01 in Overweight\/Obese Subjects With T2DM and NAFLD. Identifier NCT04812262; 2023 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04812262 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref111","unstructured":"A Study of LY3549492 in Healthy Participants. Identifier NCT04758234; 2022 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04758234 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref112","unstructured":"Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy. Identifier NCT04504396; 2023 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04504396 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref113","unstructured":"Low-Dose Pioglitazone in Patients With NASH. (AIM 2). Identifier NCT04501406; 2025 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04501406 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref114","unstructured":"Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835\/PF-04971729) (MK-8835-059). Identifier NCT04029480; 2025 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04029480 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref115","unstructured":"Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight\/Obese Men With T2DM or Prediabetes and Hypogonadism (Test2Func); 2025 [Internet]. Identifier NCT03851627. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03851627 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref116","unstructured":"Lanifibranor in Patients With Type 2 Diabetes &amp; Nonalcoholic Fatty Liver Disease. Identifier NCT03459079; 2023 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03459079 [cited 2025 Mar 17]."},{"key":"10.23736\/S0031-0808.25.05314-5_ref117","unstructured":"BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME). Identifier NCT01131676; 2016 [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01131676 [cited 2025 Mar 17]."}],"container-title":["Panminerva Medica"],"original-title":[],"link":[{"URL":"https:\/\/www.minervamedica.it\/pdf.php?cod=R41Y2025N02A0087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T06:37:20Z","timestamp":1748932640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.minervamedica.it\/index2.php?show=R41Y2025N02A0087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":117,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.23736\/s0031-0808.25.05314-5","relation":{},"ISSN":["0031-0808","1827-1898"],"issn-type":[{"value":"0031-0808","type":"print"},{"value":"1827-1898","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}